For pricing in CAD please contact us

Tissue Transglutaminase - 0.2mg

Tissue Transglutaminase - 0.2mg

Regular price
$517.04 USD
Regular price
Sale price
$517.04 USD
Unit price
Sold out

transglutaminase 2

Uniprot ID:  P21980
mRNA RefSeq:  NM_004613 NM_198951 
Protein RefSeq:  NP_004604 NP_945189
Size: 0.2mg
Source: Recombinant
Catalogue Number: ATT01-02

Product Information

tTG is the most widely distributed member of the transglutaminase family, being expressed in almost all cell types. Belonging to a family of calcium dependent enzymes it has been found to be expressed in up to 8 different isoforms, depending on its loci within tissues. Enzymatically tTG is known to play a role in tissue repair, specifically in remodelling functions whilst also exhibiting protective and preventative properties. The enzyme is 687 amino acids in length with a molecular weight of around 80kDa with 4 domains, an N-terminal beta sandwich domain, catalytic core and 2 C-terminal beta barrel domains.

The activity of the enzyme may play a role in cross-linking of proteins by formation of covalent bonds between glutamine and lysine or conversion from glutamine to glutamic acid. Deamidation occurs under mildly acidic conditions which leads to a series of T-cell stimulatory gluten peptides. Type 2 tTG is now known to play a significant role in autoimmune diseases, with the type 3 isoform found to be present in dermatitis herpetiformis. A significantly increased expression in the mucosa is found in patients suffering from Coeliac disease. Anti-tTG autoantibodies of both IgA and IgG classes originate from B lymphocytes in the intestinal mucosa of CD patients, with IgA anti-tTG considered to be highly specific as a clinical marker for CD. The target epitope region is conformation dependent, suggesting pathogenicity due to the antibody response, which has been seen to have an inhibitory effect on catalytic activity. Presence of these antibodies can also be used as a diagnostic marker for intestinal damage and adherence to a gluten free diet. Studies have found human anti-tTG IgA to be 98% sensitive with a specificity of 97% in adults who have coeliac disease.


PDF-logo-dl Tissue Transglutaminase datasheet

Clinical Indications

Coeliac Disease


PDF-logo-dl  Material Safety Data Sheet


Lai TS, Davies C and Greenberg CS, (2010) Human tissue transglutaminase is inhibited by pharmacologic and chemical acetylation. Protein Sci. 19(2):229-35

Schaertl S et al, (2010) A profiling platform for the characterization of transglutaminase 2 (TG2) inhibitors. J Biomol Screen. 15(5):478-87

Kurppa K et al, (2011) Antibodies against deamidated gliadin peptides in early-stage celiac disease. J Clin Gastroenterol. 45(8):673-8

Wang Z and Griffin M, (2012) TG2, a novel extracellular protein with multiple functions. Amino Acids. 42(2-3):939-49

Gundemir S et al, (2012) Transglutaminase 2: a molecular Swiss army knife. Biochim Biophys Acta. 1823(2):406-19

Pietsch M et al, (2013) Tissue transglutaminase: an emerging target for therapy and imaging. Bioorg Med Chem Lett. 23(24):6528-43

Jang TH et al, (2014) Crystal structure of transglutaminase 2 with GTP complex and amino acid sequence evidence of evolution of GTP binding site. PLoS One. 9(9):e107005

Korponay-Szabó IR, Troncone R and Discepolo V, (2015) Adaptive diagnosis of coeliac disease Best Pract Res Clin Gastroenterol.  29(3):381-98

Adriaanse M and Leffler DA, (2015) Serum markers in the clinical management of celiac disease. Dig Dis. 33(2):236-43

Dieterich W et al, (1997) Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med.  3(7):797-801

Caputo I et al, (2004) Transglutaminase 2 in celiac disease: minireview article. Amino Acids. 26(4):381-6

Van Meensel B et al, (2004) Diagnostic accuracy of ten second-generation (human) tissue transglutaminase antibody assays in celiac disease. Clin Chem. 50(11):2125-35

Bizzaro N et al, (2012) Cutting-edge issues in celiac disease and in gluten intolerance. Clin Rev Allergy Immunol. 42(3):279-87